Overview Empa/Lina FDC Food Effect Study (Japan) Status: Completed Trial end date: 2016-10-05 Target enrollment: Participant gender: Summary The trial will be performed as an open-label, randomised, single-dose, two-sequence crossover design for the assessment of effect of food on bioavailability of empagliflozin / linagliptin fixed dose combination (FDC) tablet. Phase: Phase 1 Details Lead Sponsor: Boehringer IngelheimTreatments: EmpagliflozinLinagliptin